Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis-3

DAC: PKBβ (p = 0.03), nuclear (N-) p-GSK3β (p = 0.008), EGFR (p = 0.055), N-p-ERK (p = 0.04), N-p-p38 (p = 0.03) and p-S6 (p = 0.03). (B) A representative image of centroacinar cells (arrows) and larger ducts (arrowheads) shows positive staining for p-mTOR. (C) A subset of the signaling proteins shows differential staining among the cellular components of the pancreas.<p><b>Copyright information:</b></p><p>Taken from "Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis"</p><p>http://www.biomedcentral.com/1471-2407/8/43</p><p>BMC Cancer 2008;8():43-43.</p><p>Published online 6 Feb 2008</p><p>PMCID:PMC2270852.</p><p></p

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis-0

Ucts from normal pancreas in PDAC (Dt), or ducts from non-PDAC (D). Array position is designated using x-y coordinates (A-J, 1–8), and specimens derived from the same case have identical nomenclature (T coordinates/Dt coordinates). Protein distribution is cytoplasmic unless designated as nuclear (N-). Common branches show expression similarities in specimens and proteins using an unsupervised hierarchical clustering analysis. The two largest branches contain specimens of tumor (a) and histologically normal ducts (b).<p><b>Copyright information:</b></p><p>Taken from "Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis"</p><p>http://www.biomedcentral.com/1471-2407/8/43</p><p>BMC Cancer 2008;8():43-43.</p><p>Published online 6 Feb 2008</p><p>PMCID:PMC2270852.</p><p></p

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis-2

Cimens and proteins from an unsupervised hierarchical clustering analysis.<p><b>Copyright information:</b></p><p>Taken from "Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis"</p><p>http://www.biomedcentral.com/1471-2407/8/43</p><p>BMC Cancer 2008;8():43-43.</p><p>Published online 6 Feb 2008</p><p>PMCID:PMC2270852.</p><p></p

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis-4

Ucts from normal pancreas in PDAC (Dt), or ducts from non-PDAC (D). Array position is designated using x-y coordinates (A-J, 1–8), and specimens derived from the same case have identical nomenclature (T coordinates/Dt coordinates). Protein distribution is cytoplasmic unless designated as nuclear (N-). Common branches show expression similarities in specimens and proteins using an unsupervised hierarchical clustering analysis. The two largest branches contain specimens of tumor (a) and histologically normal ducts (b).<p><b>Copyright information:</b></p><p>Taken from "Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis"</p><p>http://www.biomedcentral.com/1471-2407/8/43</p><p>BMC Cancer 2008;8():43-43.</p><p>Published online 6 Feb 2008</p><p>PMCID:PMC2270852.</p><p></p

sj-docx-1-cix-10.1177_11769351221136056 – Supplemental material for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts

Supplemental material, sj-docx-1-cix-10.1177_11769351221136056 for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts by Jessica Weiss, Nhu-An Pham, Melania Pintilie, Ming Li, Geoffrey Liu, Frances A Shepherd, Ming-Sound Tsao and Wei Xu in Cancer Informatics</p

sj-xlsx-2-cix-10.1177_11769351221136056 – Supplemental material for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts

Supplemental material, sj-xlsx-2-cix-10.1177_11769351221136056 for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts by Jessica Weiss, Nhu-An Pham, Melania Pintilie, Ming Li, Geoffrey Liu, Frances A Shepherd, Ming-Sound Tsao and Wei Xu in Cancer Informatics</p